查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842027

美國動物用藥品市場：市場規模、佔有率和趨勢分析（按產品、動物種類、給藥途徑和配銷通路分類），細分市場預測（2025-2033 年）

U.S. Veterinary Medicine Market Size, Share & Trends Analysis Report By Product, By Animal Type, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國動物用藥品市場趨勢：

據估計，2024 年美國動物用藥品市場價值為 136.1 億美元，預計到 2033 年將達到 260 億美元，2025 年至 2033 年的複合年成長率為 7.6%。

市場成長主要受全球對動物性蛋白質需求不斷成長的驅動，這推動了對更健康牲畜和高效疾病控制的需求。牲畜疾病發生率的上升進一步增加了對有效診斷和治療方案的需求。此外，頻繁的新產品發布和技術創新提高了先進獸醫解決方案的可及性，而獸醫學的持續進步則提高了動物保健的精準度和療效。

由於新產品研發、業務拓展以及為引入創新技術而建立的策略聯盟，市場正在不斷演變。這些措施正在重塑市場需求和實踐。例如，2025年2月，Align Capital Partners旗下的寵物健康平台Custom Veterinary Services (CVS)收購了Green Mountain Animal (GMA)，組成了一家名為CompletePet的綜合性寵物健康產品公司。此次合併預計將提供各種定製配方的含藥寵物飼料添加劑和健康產品，GMA位於佛蒙特州的工廠將繼續支持其創新和供應鏈能力。

此外，寵物擬人化的趨勢促使飼主更願意在寵物照護上投入更多資金，因為他們越來越重視寵物的健康和福祉。獸醫護理和寵物相關產品的支出，包括高檔食品、藥品、預防性體檢、疫苗接種、手術，甚至先進的治療，都在不斷成長。根據美國寵物用品協會預測，美國寵物支出將從2018年的905億美元成長66%，到2024年達到約1506億美元。雖然2018年至2020年間支出穩定成長，增幅為14.5%，但新冠疫情加速了這一趨勢，導致2020年至2024年間支出激增45.4%。這主要是由於寵物飼養量的增加。

此外，FDA核准Zenrelia並於2024年9月在美國上市，將透過擴大犬類過敏性皮膚炎和異位性皮膚炎等常見但難以控制的疾病的治療方法，在推動動物用藥品市場成長方面發揮關鍵作用。皮膚病是寵物就診最常見的原因之一，更有效治療方法的推出將激發獸醫和寵物主人對更佳治療效果的強烈需求。與Apoquel等現有藥物相比，Zenrelia的卓越療效不僅將使其成為更多獸醫和飼主飼主的首選治療方案，還將提高新治療方法的標準，並促進標靶治療和精準醫療領域的研究與開發。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章美國動物用藥品市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場
    • 附隨市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 動物用藥品市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析
  • 定價分析
  • 法律規範
  • 產品平臺分析
  • 主要品種動物數量估算（2021-2024 年）

第4章：美國動物用藥品市場：依產品分類的估算與趨勢分析

  • 細分儀表板
  • 美國動物用藥品市場：按產品分類的變化分析
  • 美國動物用藥品市場規模及產品趨勢分析（2021-2033）
  • 生技藥品
    • 疫苗
    • 其他生技藥品
  • 製藥
    • 殺寄生蟲劑
    • 抗感染藥物
    • 消炎（藥）
    • 止痛藥
    • 其他
  • 藥用飼料添加劑
  • 其他

第5章美國動物用藥品市場：按動物類型分類的估算與趨勢分析

  • 細分儀表板
  • 美國動物用藥品市場：按動物類型分類的變化分析
  • 美國動物用藥品市場規模及趨勢分析（依動物種類分類）（2021-2033 年）
  • 生產動物
    • 家禽
    • 豬
    • 牛
    • 綿羊和山羊
    • 其他
  • 伴侶動物
    • 狗
    • 貓
    • 馬
    • 其他

第6章：美國動物用藥品市場：依給藥途徑分類的估算與趨勢分析

  • 細分儀表板
  • 美國動物用藥品市場：按給藥途徑分類的差異分析
  • 美國動物用藥品市場規模及趨勢分析（依給藥途徑分類）（2021-2033 年）
  • 口服
  • 注射
  • 外用藥物
  • 其他

第7章：美國動物用藥品市場：按分銷管道分類的估算和趨勢分析

  • 細分儀表板
  • 美國動物用藥品市場：按分銷管道分類的波動分析
  • 美國動物用藥品市場規模及趨勢分析（按分銷管道分類）（2021-2033 年）
    • 動物診所和醫院
    • 電子商務
    • 線下零售店
    • 其他

第8章 競爭情勢

  • 市場參與企業分類
  • 企業市場分析/熱力圖分析
  • 公司市佔率分析（2024 年）
  • 公司簡介
    • Boehringer Ingelheim International GmbH
    • Zoetis
    • Merck &Co., Inc.
    • Elanco
    • Dechra Pharmaceuticals PLC
    • Ceva Sante Animale
    • Bimeda Corporate
    • Biogenesis Bago
    • Phibro Animal Health Corporation
    • Virbac
  • 策略規劃
    • 企業合併（M&A）
    • 商業夥伴關係與合作
    • 產品/服務發布
    • 其他
  • 其他主要企業名單
Product Code: GVR-4-68040-197-8

U.S. Veterinary Medicine Market Trends:

The U.S. veterinary medicine market size was estimated at USD 13.61 billion in 2024 and is projected to reach USD 26.00 billion by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The market growth is largely influenced by the rising global demand for animal protein, which increases the need for healthier livestock and efficient disease management. The growing incidence of animal diseases further amplifies the demand for effective diagnostic and treatment solutions. In addition, frequent product launches and innovations are enhancing the availability of advanced veterinary solutions, while continuous advancements in veterinary medicine are improving accuracy and outcomes in animal healthcare.

The market is continuously evolving due to research into novel product development, business expansion efforts, and strategic alliances to introduce innovative technologies. These efforts are reshaping market demand and practices. For instance, in February 2025, Align Capital Partners' pet health platform, Custom Veterinary Services (CVS), acquired Green Mountain Animal (GMA) to create a unified pet health products company called CompletePet. This merger is expected to offer a range of custom-formulated pet medicated feed additives and health products, with GMA's Vermont facility continuing to support innovation and supply chain capabilities.

Moreover, the growing trend of pet humanization has led pet owners to increasingly prioritize their pets' health and well-being, driving a willingness to spend significantly more on their care. People are spending more on veterinary care and pet-related products, including premium food, medications, preventive checkups, vaccinations, surgeries, and even advanced treatments. According to the American Pet Products Association, U.S. spending on pets rose from $90.5 billion in 2018 to around $150.6 billion in 2024, an increase of 66%. Between 2018 and 2020, spending grew steadily by 14.5%, but the COVID-19 pandemic accelerated the trend, with a 45.4% jump from 2020 to 2024, largely due to more people adopting pets.

In addition, the FDA approval and subsequent U.S. launch of Zenrelia in September 2024 are playing a pivotal role in driving the growth of the veterinary medicine market by broadening the availability of advanced therapies for widespread yet difficult-to-manage conditions such as allergic and atopic dermatitis in dogs. Skin disorders are among the most frequent reasons for veterinary visits, and introduction of more effective therapy creates strong demand from both veterinarians and pet owners seeking better outcomes. Zenrelia works better than existing drugs such as Apoquel, which not only makes more veterinarians and pet owners choose it but also raises the standard for new treatments, encouraging more research and development in targeted therapies and precision medicine.

U.S. Veterinary Medicine Market Report Segmentation

This report forecasts revenue growth provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary medicine market report based on product, animal type, route of administration, distribution channel:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
    • Vaccines
    • Modified/ Attenuated Live
    • Inactivated (Killed)
    • Other Vaccines
    • Other Biologics
  • Pharmaceuticals
    • Parasiticides
    • Anti-infectives
    • Anti-inflammatory
    • Analgesics
    • Others
  • Medicated Feed Additives
  • Others
  • Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Production Animals
    • Poultry
    • Pigs
    • Cattle
    • Sheep & Goats
    • Others
  • Companion Animals
    • Dogs
    • Cats
    • Horses
    • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Other Routes
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals & Clinics
  • E-commerce
  • Offline Retail Stores
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
    • 1.3.6. Data analysis model
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Medicine Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of chronic disease in pets
      • 3.2.1.2. Rising pet expenditure and pet humanization
      • 3.2.1.3. Technological advancements
      • 3.2.1.4. Strategic initiatives by key players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent regulatory process
      • 3.2.2.2. Increasing Influx Of Counterfeit Drugs.
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Legal landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Technological landscape
      • 3.3.2.6. Environmental landscape
  • 3.4. Pricing Analysis
  • 3.5. Regulatory Framework
  • 3.6. Product Pipeline Analysis
  • 3.7. Estimated Animal Population by key Species, 2021 - 2024

Chapter 4. U.S. Veterinary Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Medicine Market: Product Movement Analysis
  • 4.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Biologics
    • 4.4.1. Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Vaccines
      • 4.4.2.1. Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. Modified/ Attenuated
        • 4.4.2.2.1. Modified/ Attenuated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Inactivated (Killed)
        • 4.4.2.3.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.4. Other Vaccines
        • 4.4.2.4.1. Other Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Other Biologics
      • 4.4.3.1. Other Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pharmaceuticals
    • 4.5.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Parasiticides
      • 4.5.2.1. Parasiticides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Anti-Infectives
      • 4.5.3.1. Anti-Infectives Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Anti-Inflammatory
      • 4.5.4.1. Anti-Inflammatory Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Analgesics
      • 4.5.5.1. Analgesics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.6. Others
      • 4.5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Medicated Feed Additives
    • 4.6.1. Medicated Feed Additives Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others

Chapter 5. U.S. Veterinary Medicine Market: Animal Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Medicine Market: Animal Type Movement Analysis
  • 5.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by Animal Type, 2021 to 2033 (USD Million)
  • 5.4. Production Animals
    • 5.4.1. Production Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Poultry
      • 5.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Pigs
      • 5.4.3.1. Pigs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Cattle
      • 5.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Sheep & Goat
      • 5.4.5.1. Sheep & goat Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Companion Animals
    • 5.5.1. Companion Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Dogs
      • 5.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Cats
      • 5.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Horses
      • 5.5.4.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Veterinary Medicine Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Medicine Market: Route of Administration Movement Analysis
  • 6.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Injectable
    • 6.4.3. Injectable Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Topical
    • 6.4.5. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Veterinary Medicine Market: By Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Medicine Market: By End Use Movement Analysis
  • 7.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Veterinary Clinics & Hospitals
      • 7.3.1.1. Veterinary Clinics & Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. E-Commerce
      • 7.3.2.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Offline Retail Stores
      • 7.3.3.1. Offline Retail Stores Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Others
      • 7.3.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Boehringer Ingelheim International GmbH
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product/Service Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Zoetis
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product/Service Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product/Service Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Elanco
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product/Service Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Dechra Pharmaceuticals PLC
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product/Service Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Ceva Sante Animale
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product/Service Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Bimeda Corporate
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product/Service Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Biogenesis Bago
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product/Service Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Phibro Animal Health Corporation
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product/Service Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Virbac
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product/Service Benchmarking
      • 8.4.10.4. Strategic Initiatives
  • 8.5. Strategy Mapping
    • 8.5.1. Mergers & Acquisitions
    • 8.5.2. Partnerships & Collaborations
    • 8.5.3. Product/Service launch
    • 8.5.4. Others
  • 8.6. List of other key players

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 U.S. Veterinary Medicine Market, By Product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Veterinary Medicine Market, By Animal Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Veterinary Medicine Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 5 U.S. Veterinary Medicine Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 6 Company Overview
  • Table 7 Product Benchmarking
  • Table 8 Financial Performance
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modelling For Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 U.S. Veterinary Medicine Market Revenue, 2021 - 2033 (USD Million)
  • Fig. 10 U.S. Veterinary Medicine Market Snapshot
  • Fig. 11 U.S. Veterinary Medicine Market Driver Impact
  • Fig. 12 U.S. Veterinary Medicine Market Restraint Impact
  • Fig. 13 U.S. Veterinary Medicine Product Key Takeaways (USD Million)
  • Fig. 14 U.S. Veterinary Medicine Market: Product, Market Share 2024 & 2033
  • Fig. 15 Biologics Market, 2021 - 2033 (USD Million)
  • Fig. 16 Vaccines Market, 2021 - 2033 (USD Million)
  • Fig. 17 Modified/ Attenuated Live Market, 2021 - 2033 (USD Million)
  • Fig. 18 Inactivated (Killed) Market, 2021 - 2033 (USD Million)
  • Fig. 19 Other Vaccines Market, 2021 - 2033 (USD Million)
  • Fig. 20 Other Biologics Market, 2021 - 2033 (USD Million)
  • Fig. 21 Medicated Feed Additives Market, 2021 - 2033 (USD Million)
  • Fig. 22 Pharmaceuticals Market, 2021 - 2033 (USD Million)
  • Fig. 23 Parasiticides Market, 2021 - 2033 (USD Million)
  • Fig. 24 Anti-infectives Market, 2021 - 2033 (USD Million)
  • Fig. 25 Anti-inflammatory Market, 2021 - 2033 (USD Million)
  • Fig. 26 Analgesic Market, 2021 - 2033 (USD Million)
  • Fig. 27 Other Vaccines Market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Veterinary Medicine Animal Type Key Takeaways (USD Million)
  • Fig. 29 U.S. Veterinary Medicine Market: Animal Type, Market Share 2024 & 2033
  • Fig. 30 Production Animals Market, 2021 - 2033 (USD Million)
  • Fig. 31 Poultry Animals Market, 2021 - 2033 (USD Million)
  • Fig. 32 Pigs Animals Market, 2021 - 2033 (USD Million)
  • Fig. 33 Cattle Animals Market, 2021 - 2033 (USD Million)
  • Fig. 34 Sheep & Goat Animals Market, 2021 - 2033 (USD Million)
  • Fig. 35 Others Market, 2021 - 2033 (USD Million)
  • Fig. 36 Companion Animals Market, 2021 - 2033 (USD Million)
  • Fig. 37 Dogs Animals Market, 2021 - 2033 (USD Million)
  • Fig. 38 Cats Animals Market, 2021 - 2033 (USD Million)
  • Fig. 39 Horses Animals Market, 2021 - 2033 (USD Million)
  • Fig. 40 Others Market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Veterinary Medicine Route of Administration Key Takeaways (USD Million)
  • Fig. 42 U.S. Veterinary Medicine Market: Route of Administration, Market Share 2024 & 2033
  • Fig. 43 Oral Market, 2021 - 2033 (USD Million)
  • Fig. 44 Injectable Market, 2021 - 2033 (USD Million)
  • Fig. 45 Topical Market, 2021 - 2033 (USD Million)
  • Fig. 46 Others Market, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Veterinary Medicine Market By End Use: Key Takeaways
  • Fig. 48 U.S. Veterinary Medicine Market By End Use, Market Share, 2024 & 2033
  • Fig. 49 Veterinary Clinics & Hospitals Market, 2021 - 2033 (USD Million)
  • Fig. 50 E-Commerce Market, 2021 - 2033 (USD Million)
  • Fig. 51 Offline Retail Stores Market, 2021 - 2033 (USD Million)
  • Fig. 52 Others Market, 2021 - 2033 (USD Million)
  • Fig. 53 Market Participant Categorization
  • Fig. 54 Market Share Of Key Market Players U.S. Veterinary Medicine Market